NDA 016784 · B Braun
Glycine 1.5% In Plastic Container
Glycine · Irrigation
Last checked: Nov 20, 2026Latest source record: Sep 12, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1978
Feb 6, 1978
Approved uses
1
Original approval plus efficacy supplements
Registered trials
124
18 Phase 3, 9 recruiting
FAERS reports
329
262 serious, 28 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 1, 2021.
INDICATIONS AND USAGE 1.5% Glycine Irrigation USP is indicated as an irrigant during transurethral prostatic or bladder surgery.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 6, 1978 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- GLYCINE 1.5% IN PLASTIC CONTAINER · GLYCINE 1.5GM/100ML · SOLUTION, IRRIGATION · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Glycine" as an intervention, any sponsor and status, largest first.
- Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old InfantsPivotal-lookingCompleted
Sinovac Biotech Co., LtdIndustry
NCT05386810 · 1,572 participants · Start Nov 5, 2020 · Primary completion Oct 8, 2022
Drug: Experimental vaccine; IPV control vaccine and 1 more · For: Poliomyelitis
Sites: Kaifeng, China; Xuchang, China
- Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)Pivotal-lookingCompleted
Jiangsu Rec-Biotechnology Co., Ltd.Industry
NCT05084989 · 948 participants · Start Jan 31, 2022 · Primary completion Aug 18, 2022
Drug: Part1:Recombinant two-component COVID-19 vaccine (CHO cell); Part1: Placebo and 2 more · For: COVID-19
Sites: Roxas City, Philippines
- Non-specific Effects of Rabies VaccinePivotal-lookingCompleted
Ross University School of Veterinary MedicineAcademic, hospital or other
NCT03656198 · 546 participants · Start Aug 29, 2018 · Primary completion Jul 27, 2020
Drug: Rabivax-S; Sterile Water Injection · For: Influenza-like Illness; Upper Respiratory Disease; Diarrhea and 1 more
Sites: Basseterre, Saint Kitts and Nevis
- A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) MutationPivotal-lookingNot yet recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07905924 · 540 participants (planned) · Start Dec 31, 2026 · Primary completion Mar 30, 2032
Drug: RO7836748; Pembrolizumab and 2 more · For: Solid Tumors
- Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory SyndromePivotal-lookingCompleted
Maimónides Biomedical Research Institute of CórdobaAcademic, hospital or other
NCT04366908 · 517 participants · Start May 7, 2020 · Primary completion Apr 19, 2022
Drug: BAT + Calcifediol; BAT · For: SARS-CoV 2; COVID19; SARS (Severe Acute Respiratory Syndrome) and 2 more
Sites: Córdoba, Spain
- Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19Pivotal-lookingCompleted
CytoDyn, Inc.Industry
NCT04347239 · 484 participants · Start Apr 16, 2020 · Primary completion Oct 24, 2021
Drug: Placebo; Leronlimab (700mg) · For: Coronavirus Disease 2019
Sites: Alexander City, Alabama; Fullerton, California; Los Angeles, California · 18 sites in all
- Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in BangladeshPivotal-lookingCompleted
PATHAcademic, hospital or other
NCT02531802 · 475 participants · Start Oct 2015 · Primary completion Jul 29, 2017
Drug: ETVAX; dmLT · For: Escherichia Coli Diarrhea
Sites: Dhaka, Bangladesh
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-MPivotal-lookingActive, not recruiting
University of OxfordAcademic, hospital or other
NCT07183371 · 360 participants (planned) · Start Dec 15, 2025 · Primary completion Mar 2027
Drug: R21; RH5.1 and 5 more · For: Malaria,Falciparum
Sites: Nanoro, Burkina Faso
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective37
- nausea29
- pneumonia27
- off label use26
- fatigue25
- condition aggravated24
- rash23
- insomnia22
- status epilepticus22
- stevens-johnson syndrome22
- depressed level of consciousness21
- sopor21
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 10 |
| 2013 | 10 |
| 2014 | 5 |
| 2015 | 11 |
| 2016 | 18 |
| 2017 | 35 |
| 2018 | 38 |
| 2019 | 11 |
| 2020 | 24 |
| 2021 | 20 |
| 2022 | 32 |
| 2023 | 25 |
| 2024 | 38 |
| 2025 | 27 |
| 2026 | 20 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial.
Kumar P, Liu C, Suliburk J, et al. · J Gerontol A Biol Sci Med Sci 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis.
Guasch-Ferré M, Hruby A, Toledo E, et al. · Diabetes Care 2016 · Meta-Analysis, Systematic Review
- Effects of breaking up prolonged sitting via exercise snacks intervention on the body composition and plasma metabolomics of sedentary obese adults: a randomized controlled trial.
Zhou J, Gao X, Zhang D, et al. · Endocr J 2025 · Randomized Controlled Trial
- The glutamatergic system in Alzheimer's disease: a systematic review with meta-analysis.
Soares C, Da Ros LU, Machado LS, et al. · Mol Psychiatry 2024 · Systematic Review, Meta-Analysis
- Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies.
Morze J, Wittenbecher C, Schwingshackl L, et al. · Diabetes Care 2022 · Meta-Analysis, Research Support, N.I.H., Extramural
- The effect of glycine administration on the characteristics of physiological systems in human adults: A systematic review.
Soh J, Raventhiran S, Lee JH, et al. · Geroscience 2024 · Systematic Review
Sponsor: B Braun
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.